Premier Journal of Cardiology

About the Premier Journal of Cardiology (PJC)

The Premier Journal of Cardiology (PJC) is a leading journal of cardiology, publishing open-access, peer-reviewed, quarterly studies to advance cardiovascular research and heart health innovation. Published by Premier Science, PJC fosters interdisciplinary collaboration, uniting experts to address challenges like AI-driven diagnostics and heart failure management.

Publication frequency: quarterly
Indexing: Google ScholarUlrichsweb and others
Archived: British Library and Portico
ISSN: 2977-8972

Aims and Scope

As a distinguished cardiology research journal, PJC champions global advancements in cardiovascular science. Its peer-reviewed studies span critical domains, including:

  • Heart Failure Management
  • Cardiac Imaging
  • Coronary Artery Disease
  • Arrhythmias
  • Interventional Cardiology
  • Preventive Cardiology

The PJC provides accessible, high-impact cardiology articles, shedding light on AI-driven diagnostics, lifestyle interventions, and cutting-edge treatments.

Premier Journal of Cardiology Articles

The Premier Journal of Cardiology articles showcase pioneering research in cardiovascular science and clinical practice. Dive into the latest studies in this leading journal of cardiology and contribute your findings via the eWorkFlow portal to shape heart research across the world. 

Article types – research, reviews, editorials/perspectives and correspondence-style articles will be considered.

Premier Journal of Cardiology

Archive

Volume 6 – January – March 2026

Volume 5 – October – December 2025

Volume 4 – July – September 2025

Volume 3 – April – June 2025

Volume 2 – January – March 2025

Volume 1 – October-December 2024

FAQs


Volume 6 – January – March 2026

Fig 2 | Vaughan Williams’ classification of antiarrhythmic drugs. The illustration depicts the four major classes of antiarrhythmic agents, their sites of action on the cardiac action potential, and representative drug examples. Other agents are grouped under “others”
Rhythm Control and Risk Reduction: Evidence From a Narrative Review on Therapeutic Advances in Cardiac Arrhythmia Management
Saheed E. Sanyaolu1 ORCiD, Omobolanle I. Ogundele2, Matthew O. Ogbe3, Obumneme J. Nweke4, Halimah O. Alao5, Fadilulahi A. Usman6, Michealin U. Coker7, Habeebat O. Oludaisi1 and Olufemi S. Akinmeji1
1. Faculty of Pharmacy, Olabisi Onabanjo University, Ago-Iwoye, Ogun State, Nigeria
2. Department of Pharmacognosy, Faculty of Pharmacy, University of Lagos, Lagos, Nigeria
3. American Chemical Society, 1500 South Avenue K, Portales, USA
4. Enugu State College of Medicine, Parklane GRA, Enugu, Enugu State, Nigeria
5. Department of Pharmacognosy, University of Ilorin, Kwara State, Nigeria
6. Department of Molecular Biology and Biotechnology, Nigerian Institute of Medical Research, Lagos, Nigeria
7. Faculty of Pharmacy, University of Benin, Benin City, Edo State, Nigeria
Premier Journal of Cardiology 2026;6:100014

Volume 5 – October – December 2025

Fig 1 | Mechanistic insights of quercetin, EGCG, and anthocyanins against hypertension and dyslipidemia
Nutraceuticals Against the Silent Killers: Role of Secondary Metabolites in the Prevention and Management of Hypertension and Hyperlipidemia
Muhammad Qamar1, Eisha Ismail2, Muhammad Zulqarnain Khan1, Bushra Irum Fatim1,
Maryam Jalal Ud Din1 and Malik Waseem Abbas3
1. Department of Food Science and Technology, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan, Pakistan
2. Multan Medical and Dental College, Multan, Pakistan
3. Institute of Chemical Sciences, Bahauddin Zakariya University, Multan, Pakistan
Premier Journal of Cardiology 2025;5:100013

Volume 4 – July – September 2025

Fig 2 | Echocardiographic representation of a professional soccer player’s heart by Kim et al.68
Impact of Moderate and Vigorous Physical Activity on Cardiovascular Health: A Review
Vedran Radonić
Department of Cardiology, University Hospital Merkur, Zagreb, Croatia
Premier Journal of Cardiology 2025;4:100012
Fig 1 | Modifiable and non-modifiable risk factors of atherosclerosis
Current Evidence on the Clinical Management of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review
Saheed E. Sanyaolu1, Diana O. Wilson2, Blessing A. Oguntolu1, Mautin S. Salako1 and Rukayat O. Adeyemi1
1. Department of Pharmacy, Olabisi Onabanjo University, Ago-Iwoye, Ogun State, Nigeria
2. Department of Clinical Pharmacy, Niger Delta University, Wilberforce Island, Bayelsa, Nigeria
Premier Journal of Cardiology 2025;4:100011
Fig 3 | Applications of radiomics in cardiology
Radiomics-based Diagnosis in Cardiology: Advances and Prospects
Saheed E. Sanyaolu1, Oluwaseun O. Adekoya2, Aishat O. Olalekan1, Habeebat O. Oludaisi1, Tawakaltu O. Banjoko1 and Adeniyi J. Aroworade1
1. Faculty  of Pharmacy, Olabisi Onabanjo University, Ago-Iwoye, Ogun State, Nigeria
2. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Canada.
Premier Journal of Cardiology 2025;4:100010

Volume 3 – April – June 2025

Fig 2 | Visualizes the incidence rates of various complications from highest to lowest maximum incidence rate using a dual-color approach where the darker blue shows the minimum incidence rate and the lighter blue extends to show the maximum rate, giving you a clear picture of both the baseline risk and the potential range for each complication
The Key Takeaways from the 2024 EHRA/HRS/APHRS/LAHRS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation
Narendra Kumar
HeartbeatsZ Academy, Norfolk, UK
Premier Journal of Cardiology 2025;3:100009
Fig 1 | New York heart association classification of heart failure
Recent Advancements in the Management of Heart Failure: A Review
Saheed Ekundayo Sanyaolu
Faculty of Pharmacy, Olabisi Onabanjo University, Ago-Iwoye, Nigeria
Premier Journal of Cardiology 2025;3:100008

Volume 2 – January – March 2025

Fig 1 | Paclitaxel structure18
Evidence on Treating Coronary Artery Disease with Drug-Coated Balloons
Vedran Radonić
Department of Cardiology, University Hospital Merkur, Zagreb, Croatia
Premier Journal of Cardiology 2025;2:100007
Fig 2 | Examples of machine learning algorithms
Integration of Machine Learning in Imaging Analysis for Clinical Diagnosis of Cardiovascular Diseases
Saheed Sanyaolu
Olabisi Onabanjo University, Ago-Iwoye, Nigeria
Premier Journal of Cardiology 2025;2:100006
Fig 1 | Advancements in AI for precision diagnosis and treatment of MI: A comprehensive review of clinical trials and randomized controlled trials20
Using AI to Diagnose Myocardial Infarction: A Review of the Evidence Behind Machine Learning Application to the Emergency Chest Pain Patient
Oliver Smith
Freelance Writer, Portsmouth, United Kingdom
Premier Journal of Cardiology 2025;2:100005
The Effectiveness of Plant-Based Diet on Cardiovascular Health
Jostel Owusu Akua Yeboawaa
Freelance Writer, Accra, Ghana
Premier Journal of Cardiology 2025;2:100004
Fig 2 | AI in cardiac imaging: regulatory and economic considerations
Artificial Intelligence in Cardiac Imaging: A Comprehensive Review of Clinical Implementation and Validation
Amita Kajrolkar
Freelance Writer, Mumbai, India
Premier Journal of Cardiology 2025;2:100003
Fig 2 | Milrinone inhibits phosphodiesterase III enzyme (PDE-III). This increases cyclic adenosine monophosphate (cAMP), activating phosphokinase A (PKA). PKA promotes the influx of calcium ions through L-type calcium channels (LTCC) and ryanodine receptors (RyR) into the cytosol. ATP: adenosine triphosphate; PLB: phospholamban; PDE: phosphodiesterase; Gαi: G inhibitory alpha protein; Gαs: G stimulatory alpha protein; SERCA: sarcoplasmic reticulum calcium ATPase
Unlocking the Potential of Prophylactic Milrinone in Off-Pump Coronary Artery Bypass Grafting: A Narrative Review
Manoranjan Padhi, Dharmajivan Samantaray, Manmaya Padhy and Sweta Mohanty
Department of Cardiothoracic and Vascular Anaesthesia, Care Hospital, Bhubaneswar, Odisha, India
Premier Journal of Cardiology 2025;2:100002

Volume 1 – October-December 2024

Fig 3 | Characteristics of the impacts of environmental influencers in cardiovascular disease
The Influence of Environmental Factors on Cardiovascular Disease Risk: A Comprehensive Review
Ambreen Ilyas, Khadija Batool and Hina Javed
School of Biological Sciences, University of the Punjab, Lahore, Pakistan
Premier Journal of Cardiology 2024;1:100001

Premier Journal of Cardiology FAQs

Does the PJC publish research on emerging technologies in cardiology?

Yes. PJC actively encourages submissions that explore the clinical application of new technologies, including artificial intelligence in cardiac imaging, machine learning for risk prediction, and digital health tools for cardiovascular monitoring. 

Can early-career researchers submit work to the PJC? 

Yes. The PJC supports contributions from early-career researchers, including fellows and postgraduates. We especially encourage submissions from emerging voices presenting novel perspectives or underrepresented global populations. 

What are the key focus areas for submissions to the PJC?

PJC prioritises high-quality research in areas such as atrial fibrillation management, heart failure therapies, interventional cardiology, cardiovascular imaging, and the application of AI and machine learning in cardiac diagnostics and treatment. However, all areas within the field are welcome to be submitted via our eWorkFlow portal

Premier Science
Publishing Science that inspires